Xiamen Kingdomway Group Co
SZSE:002626
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (2.3), the stock would be worth ¥19.06 (25% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.8 | ¥15.21 |
0%
|
| 3-Year Average | 2.3 | ¥19.06 |
+25%
|
| 5-Year Average | 2.5 | ¥21.15 |
+39%
|
| Industry Average | 2 | ¥17.25 |
+13%
|
| Country Average | 1.9 | ¥16.27 |
+7%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Xiamen Kingdomway Group Co
SZSE:002626
|
9.3B CNY | 1.8 | 19.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 8.9 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 3.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 2.6 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | -9.1 | 4 516.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Xiamen Kingdomway Group Co
Glance View
Xiamen Kingdomway Group Co., rooted firmly in the bustling industrial city of Xiamen, China, has carved a unique niche within the health and nutrition sector. The company's journey is emblematic of strategic diversification and industry foresight. Originating as a manufacturer of vital active pharmaceutical ingredients, Kingdomway quickly harnessed its expertise and infrastructure to expand into the production of vitamins, nutritional supplements, and health-care products. This strategic expansion allowed the company to capture various segments of the health market, not only focusing on pharmaceuticals but also venturing into consumer health goods. Integral to its business model is leveraging advanced biotechnology and robust research capabilities, ensuring consistent innovation and the delivery of high-quality products that cater to global health and wellness demands. The financial engine of Xiamen Kingdomway turns on the adept integration of rigorous research and development with a vast, diversified distribution network. The company has built a vertically integrated supply chain, which provides a competitive edge in controlling production costs while maintaining stringent quality standards. Through strategic alliances and investments in key markets worldwide, Kingdomway enhances its footprint and taps into the expanding consumer base eager for health and wellness solutions. Its significant revenue streams flow from both domestic sales and international exports, with an adept marketing strategy that positions its offerings in numerous global markets. By emphasizing continuous improvement and customer-centric innovation, Xiamen Kingdomway ensures a strong positioning amid the dynamic landscape of the wellness industry.